Document Specialty Meds in the EHR, Even if You're NOT the Prescriber
March 2016
You'll hear more about specialty meds...Repatha (evolocumab), Harvoni (ledipasvir/sofosbuvir), Gleevec (imatinib), etc.
Specialty meds account for about half of new drugs approved in 2015...and these meds will make up over half of drug spending by 2017.
What makes specialty meds "special"? They're generally high-cost and "high-touch"...such as requiring specific testing before starting the med, a detailed monitoring plan, or unique storage.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote